SYTL3

Across TCGA pan-cancer cohorts, SYTL3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SYTL3 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SYTL3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SYTL3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

LUAD, UCEC, and SCLC are the cancer types where SYTL3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.004	0.835	<.001	34	view →
UCEC	DFS	Median	II,III,IV	0.949	0.710	.014	14	view →
SCLC	OS	Median	All	0.219	0.706	.011	6	view →
BLCA	OS	Median	II,III,IV	1.000	0.700	.021	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SYTL3–LUAD (OS)

Open the LUAD breakdown →